These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

336 related items for PubMed ID: 22826617

  • 1. Polo-like kinase 1, a new therapeutic target in hepatocellular carcinoma.
    Mok WC, Wasser S, Tan T, Lim SG.
    World J Gastroenterol; 2012 Jul 21; 18(27):3527-36. PubMed ID: 22826617
    [Abstract] [Full Text] [Related]

  • 2. Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma.
    Wang D, Chang R, Wang G, Hu B, Qiang Y, Chen Z.
    Anticancer Agents Med Chem; 2017 Jul 21; 17(7):948-954. PubMed ID: 27671301
    [Abstract] [Full Text] [Related]

  • 3. Targeting polo-like kinase 1 enhances radiation efficacy for head-and-neck squamous cell carcinoma.
    Gerster K, Shi W, Ng B, Yue S, Ito E, Waldron J, Gilbert R, Liu FF.
    Int J Radiat Oncol Biol Phys; 2010 May 01; 77(1):253-60. PubMed ID: 20394857
    [Abstract] [Full Text] [Related]

  • 4. STK39 is a novel kinase contributing to the progression of hepatocellular carcinoma by the PLK1/ERK signaling pathway.
    Zhang C, Wang X, Fang D, Xu P, Mo X, Hu C, Abdelatty A, Wang M, Xu H, Sun Q, Zhou G, She J, Xia J, Hui KM, Xia H.
    Theranostics; 2021 May 01; 11(5):2108-2122. PubMed ID: 33500714
    [Abstract] [Full Text] [Related]

  • 5. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells.
    Zhang Y, Du XL, Wang CJ, Lin DC, Ruan X, Feng YB, Huo YQ, Peng H, Cui JL, Zhang TT, Wang YQ, Zhang H, Zhan QM, Wang MR.
    Gastroenterology; 2012 Mar 01; 142(3):521-530.e3. PubMed ID: 22108192
    [Abstract] [Full Text] [Related]

  • 6. Regulation of cell apoptosis and proliferation in pancreatic cancer through PI3K/Akt pathway via Polo-like kinase 1.
    Mao Y, Xi L, Li Q, Cai Z, Lai Y, Zhang X, Yu C.
    Oncol Rep; 2016 Jul 01; 36(1):49-56. PubMed ID: 27220401
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Efficient inhibition of human colorectal carcinoma growth by RNA interference targeting polo-like kinase 1 in vitro and in vivo.
    Xu WJ, Zhang S, Yang Y, Zhang N, Wang W, Liu SY, Tian HW, Dai L, Xie Q, Zhao X, Wei YQ, Deng HX.
    Cancer Biother Radiopharm; 2011 Aug 01; 26(4):427-36. PubMed ID: 21797676
    [Abstract] [Full Text] [Related]

  • 11. Polo-like kinase 1 contributes to the tumorigenicity of BEL-7402 hepatoma cells via regulation of Survivin expression.
    He Z, Wu J, Dang H, Lin H, Zheng H, Zhong D.
    Cancer Lett; 2011 Apr 28; 303(2):92-8. PubMed ID: 21330050
    [Abstract] [Full Text] [Related]

  • 12. Polo-like kinase 1 is overexpressed in renal cancer and participates in the proliferation and invasion of renal cancer cells.
    Zhang G, Zhang Z, Liu Z.
    Tumour Biol; 2013 Jun 28; 34(3):1887-94. PubMed ID: 23494182
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. CDK1-PLK1/SGOL2/ANLN pathway mediating abnormal cell division in cell cycle may be a critical process in hepatocellular carcinoma.
    Li L, Huang K, Zhao H, Chen B, Ye Q, Yue J.
    Cell Cycle; 2020 May 28; 19(10):1236-1252. PubMed ID: 32275843
    [Abstract] [Full Text] [Related]

  • 15. Therapeutic targeting of PLK1 in TERT promoter-mutant hepatocellular carcinoma.
    Tang Q, Hu G, Sang Y, Chen Y, Wei G, Zhu M, Chen M, Li S, Liu R, Peng Z.
    Clin Transl Med; 2024 May 28; 14(5):e1703. PubMed ID: 38769666
    [Abstract] [Full Text] [Related]

  • 16. Discovery of methyl 3-((2-((1-(dimethylglycyl)-5-methoxyindolin-6-yl)amino)-5-(trifluoro-methyl) pyrimidin-4-yl)amino)thiophene-2-carboxylate as a potent and selective polo-like kinase 1 (PLK1) inhibitor for combating hepatocellular carcinoma.
    Deng Z, Chen G, Liu S, Li Y, Zhong J, Zhang B, Li L, Huang H, Wang Z, Xu Q, Deng X.
    Eur J Med Chem; 2020 Nov 15; 206():112697. PubMed ID: 32814244
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Diosgenin potentiates the anticancer effect of doxorubicin and volasertib via regulating polo-like kinase 1 and triggering apoptosis in hepatocellular carcinoma cells.
    Yousef EH, El-Mesery ME, Habeeb MR, Eissa LA.
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Jul 15; 397(7):4883-4894. PubMed ID: 38165424
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.